WAVEMAN · COMPANY

ZURA · Zura Bio Ltd

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ZURA

Name: Zura Bio Ltd (ZURA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Zura Bio Ltd

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001855644

FORM 144 · 4☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

59 funds added or opened last quarter

below 52% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

4 insiders have filed intent to sell ($946.6K) and have not sold yet.

59 funds added or opened positions in the latest 13F quarter, of 97 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +208.4%

+208.4%12M

INSIDER BUY13D/G STAKEFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 59 funds added last quarter, $946.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Zura Bio Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Access Industries Holdings LLC

—

BUY

2026-02-26

2,000,000.0

$12.5M

Thiara Parvinder

Director

SELL

2024-11-25

1,001,633.0

$2.7M

Thiara Parvinder

Director

SELL

2024-09-11

3,800,000.0

$10.3M

Sidhu Someit

Director

SELL

2024-09-04

51,728.0

$200.2K

Ploos van Amstel Arnout

Director

BUY

2024-05-17

80,000.0

$496.0K

11 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 6 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

MONTANOVA CAPITAL, LLC

9,443,001.0 sh

$55.7M

Venrock Adviser, LLC

6,434,990.0 sh

$38.0M

MPM BIOIMPACT LLC

4,472,843.0 sh

$26.4M

GREAT POINT PARTNERS LLC

4,215,930.0 sh

$24.9M

JPMORGAN CHASE & CO

4,354,715.0 sh

$24.5M

5%+ owners

13D = intent to influence · 13G = passive

Athanor Capital

ACTIVIST 13D · 2026-01-27

15.7%

UGS Capital LLC

ACTIVIST 13D · 2026-01-27

15.7%

Planned sales · Form 144

Filed before the sale — intent, not a trade

SOMEIT SIDHU

FILED 2026-08-18

$287.7K

SOMEIT SIDHU

FILED 2026-08-17

$151.3K

SOMEIT SIDHU

FILED 2026-08-14

$220.5K

SOMEIT SIDHU

FILED 2026-08-13

$287.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ALPS Medical Breakthroughs ETF

$383.6K POSITION · AS OF 2026-02-28

0.3%

Avantis U.S. Small Cap Equity Fund

$13.9K POSITION · AS OF 2026-02-28

0.0%

Avantis U.S. Small Cap Equity ETF

$223.3K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$2.9M POSITION · AS OF 2026-03-31

0.0%

Total Stock Market Index Trust

$6.9K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 2 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
OPERATING INCOME	$-75.2M	$-55.2M	$-62.6M	$-2.7M
NET INCOME	$-68.7M	$-52.4M	$-60.4M	$-25.7M
EPS (DILUTED)	-1.06	-0.60	-2.09	—
OPERATING CASH FLOW	$-64.8M	$-28.1M	$-15.1M	$-1.1M
CASH	$109.4M	$176.5M	$99.8M	$13.8K

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE